2-21007986-T-C
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_000384.3(APOB):c.8882A>G(p.Asn2961Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000192 in 1,614,096 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N2961I) has been classified as Likely benign.
Frequency
Consequence
NM_000384.3 missense
Scores
Clinical Significance
Conservation
Publications
- hypercholesterolemia, autosomal dominant, type BInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- familial hypobetalipoproteinemia 1Inheritance: AR, AD, SD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen
- homozygous familial hypercholesterolemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| APOB | NM_000384.3 | c.8882A>G | p.Asn2961Ser | missense_variant | Exon 26 of 29 | ENST00000233242.5 | NP_000375.3 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| APOB | ENST00000233242.5 | c.8882A>G | p.Asn2961Ser | missense_variant | Exon 26 of 29 | 1 | NM_000384.3 | ENSP00000233242.1 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152178Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000995 AC: 25AN: 251196 AF XY: 0.000125 show subpopulations
GnomAD4 exome AF: 0.000201 AC: 294AN: 1461800Hom.: 0 Cov.: 37 AF XY: 0.000204 AC XY: 148AN XY: 727202 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000105 AC: 16AN: 152296Hom.: 0 Cov.: 33 AF XY: 0.0000671 AC XY: 5AN XY: 74480 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Hypercholesterolemia, autosomal dominant, type B;C4551990:Familial hypobetalipoproteinemia 1 Uncertain:2Benign:1
- -
- -
- -
not provided Uncertain:2
The APOB c.8882A>G (p.Asn2961Ser) variant has been reported in the published literature in individuals with familial hypercholesterolemia (PMID: 35913489 (2022), 31153816 (2019)). The frequency of this variant in the general population, 0.00026 (13/50712 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
- -
Cardiovascular phenotype Uncertain:2
The p.N2961S variant (also known as c.8882A>G), located in coding exon 26 of the APOB gene, results from an A to G substitution at nucleotide position 8882. The asparagine at codon 2961 is replaced by serine, an amino acid with highly similar properties. This alteration has been noted in hypercholesterolemia cohorts and has been reported in combination with other cardiac-related genes (Beaudoin M et al. Circ Cardiovasc Genet, 2012 Oct;5:547-54; Sánchez-Hernández RM et al. J Clin Lipidol, 2019 May;13:618-626; Sustar U et al. Genet Med, 2022 Oct;24:2103-2111). This amino acid position is not well conserved in available vertebrate species, and serine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at